Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017)
Coherus Oncology's Current Deferred Revenue came in at $669,000 for Q1 2017, down 98.7% from $49.63 million a year earlier and down 25.0% from the prior quarter.
Powered by 
Analysis
Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017) Analysis & Trends
At the end of FY2016, Coherus Oncology's Current Deferred Revenue was $892,000, down 98.2% from FY2015.
- Current Deferred Revenue carries a three-year compound annual growth rate of -60.3% (FY2013 to FY2016).
- Going back by year, Current Deferred Revenue was $49.62 million in FY2015 (+117.6%), $22.8 million in FY2014 (+59.6%) and $14.28 million in FY2013.
- The Q1 2017 figure represents the lowest quarterly Current Deferred Revenue in data going back to Q4 2013.
- Year-over-year, Current Deferred Revenue has declined for three consecutive quarters, with growth averaging 7.9% over the last seven quarters.
- The fastest year-over-year change in Current Deferred Revenue over five years came in Q1 2016 (growth of 117.7%), and the weakest in Q1 2017 (a decline of 98.7%).
- Business Quant data shows CHRS's Current Deferred Revenue at $892,000 (Q4 2016), $1.38 million (Q3 2016) and $61.26 million (Q2 2016) in the three quarters before Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn |
| 10 | Coherus Oncology | 155.59 Mn | -480.55 Mn | 10.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 669,000.00 |
| Dec 31, 2016 | 892,000.00 |
| Sep 30, 2016 | 1.38 Mn |
| Jun 30, 2016 | 61.26 Mn |
| Mar 31, 2016 | 49.63 Mn |
| Dec 31, 2015 | 49.62 Mn |
| Sep 30, 2015 | 28.85 Mn |
| Jun 30, 2015 | 31.01 Mn |
| Mar 31, 2015 | 22.80 Mn |
| Dec 31, 2014 | 22.80 Mn |
| Sep 30, 2014 | 25.18 Mn |
| Dec 31, 2013 | 14.28 Mn |
API Access
Coherus Oncology Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=CHRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();